The Clinical Support Services Core will provide: 1. Data entry of laboratory and clinical trial results (Projects I, II and III). 2. Long-term follow-up of all patients entered into the Phase I/II clinical trials during present and previous grant periods (Project III). 3. A liaison between the John Wayne Cancer Institute and centers participating in the Phase III vaccine trial (Project III). 4. Clinical training and quality control of the Phase III vaccine trial, including logistical support (Project III). 5. Logistical support for the External Advisory Committee. 6. Logistical Support for the Data Monitoring Committee. 7. Coordination of data from Projects I, II, and III for presentation and publication. 8. Overall management and coordination of clerical needs (Projects I, II, and III).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA012582-30
Application #
6424515
Study Section
Project Start
2001-02-23
Project End
2002-01-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
30
Fiscal Year
2001
Total Cost
$53,375
Indirect Cost
Name
John Wayne Cancer Institute
Department
Type
DUNS #
556074458
City
Santa Monica
State
CA
Country
United States
Zip Code
90404
Dükel, Muzaffer; Streitfeld, W Scott; Tang, Tsz Ching Chloe et al. (2016) The Breast Cancer Tumor Suppressor TRIM29 Is Expressed via ATM-dependent Signaling in Response to Hypoxia. J Biol Chem 291:21541-21552
Kiyohara, Eiji; Hata, Keisuke; Lam, Stella et al. (2014) Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients. Methods Mol Biol 1102:513-22
Greenberg, Edward S; Chong, Kelly K; Huynh, Kelly T et al. (2014) Epigenetic biomarkers in skin cancer. Cancer Lett 342:170-7
Chiu, Connie G; Nakamura, Yoshitaka; Chong, Kelly K et al. (2014) Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem 60:873-85
Faries, Mark B; Steen, Shawn; Ye, Xing et al. (2013) Late recurrence in melanoma: clinical implications of lost dormancy. J Am Coll Surg 217:27-34; discussion 34-6
Kidner, Travis B; Morton, Donald L; Lee, Delphine J et al. (2012) Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716-20
Hoshimoto, Sojun; Shingai, Tatsushi; Morton, Donald L et al. (2012) Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol 30:3819-26
Hoshimoto, Sojun; Kuo, Christine T; Chong, Kelly K et al. (2012) AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol 132:1689-97
Faries, Mark B; Morton, Donald L (2012) Staging of regional nodes in pulmonary malignancies. Ann Surg Oncol 19:703-5
Hoshimoto, Sojun; Faries, Mark B; Morton, Donald L et al. (2012) Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg 255:357-62

Showing the most recent 10 out of 238 publications